Background and objective
RRP is a rare disease caused by human papillomavirus (HPV), resulting in infections and papilloma lesions (warts) in the respiratory tract [1]. The burden of the disease can be substantial for individuals with RRP, leading to frequent hospitalizations and potential surgeries [2]. Previous research has estimated that over 90% of all RRP cases are caused by HPV types 6 & 11 [3]. The vaccine Gardasil provides protection against both of these HPV types and was previously utilized in school vaccination programs from 2009 to 2016.
We are now investigating the vaccine effectiveness and incidence rate of RRP in both adults and children. This is being done through two parallel projects:
In the project "Effect of the HPV vaccine Gardasil against Laryngeal papillomatosis (AoRRP)," the primary objective is to examine whether vaccination with GARDASIL/GARDSIL9 before the age of 17 reduces the risk of RRP diagnosed in adulthood (after the age of 15). The secondary objective is to investigate the incidence rate of RRP in both genders (ages 0-31) in Norway from 2008 to 2021.
In the project "Effect of GARDASIL/GARDASIL9 against juvenile onset laryngeal papillomatosis in Sweden, Denmark, and Norway (JoRRP)," we aim to investigate whether the risk of JoRRP is lower for children whose mothers are fully vaccinated with GARDASIL/GARDASIL 9 at least one year before the age of 17, compared to children with unvaccinated mothers. The JoRRP project is conducted in collaboration with the Danish Cancer Society and the Karolinska Institute in Sweden.
Results from the project will be published in open access journals.
Status: The project is awaiting data access from Helsedata.no
Participant information
Right to Reservation and Information Security:
The RRP study utilizes health information from the Norwegian Patient Registry (NPR), Prescription Database (LMR), National Vaccination Registry (SYSVAK), as well as socio-economic data from Statistics Norway (SSB).
The availability of this information has been approved under the authority of the Health Registry Act, sections 19b and 19c.
A personal consequence assessment has been conducted and approved by the Data Protection Officer at Oslo University Hospital (OUS).
Your rights to access your information:
You have the right to access the information that is stored about you. If you wish to access your information, this request should be directed directly to the relevant registry. Information on how to request access to the various registries can be found by following the links below:
Presciption database - The Norwegian patient registry - National vaccination Registry - Statistics Norway
Contact Information
Project Leader
Ståle Nygård
Phone: 22928717
Email: stny@kreftregisteret.no
Project participants
Tom Erik Nilsen, Elen Johanne Lahlum and Madleen Orumaa
Tom Nilsen
Phone: 22928813
Email: toen@kreftregisteret.no
If you have questions about the data privacy in the project, you can contact the Data Protection Officer: personvern@ous-hf.no
Read more about data privacy at The Cancer Registry of Norway here.
Financing and collaborations
The RRP studies are financed by Merck & Co, Inc. The AoRRP study is conducted in collaboration with Merck, while the JoRRP study is conducted in collaboration with Merck, the Danish Cancer Society (Kræftens Bekempelse) in Denmark and the Karolinska Institute in Sweden.
Project Period: 2023 - 2028
Approval: The projects have been approved by the Regional Ethical Committee (REK):
AoRRP - #552356
JoRRP - #565561
References
1. Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS. 2010 Jun;118(6-7):450-4. doi: 10.1111/j.1600-0463.2010.02619.x. PMID: 20553527.
2. Taliercio S, Cespedes M, Born H, Ruiz R, Roof S, Amin MR, Branski RC. Adult-onset recurrent respiratory papillomatosis: a review of disease pathogenesis and implications for patient counseling. JAMA Otolaryngol Head Neck Surg. 2015 Jan;141(1):78-83. doi: 10.1001/jamaoto.2014.2826. PMID: 25393901.
3. Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B, Souza CA, Marchiori E. Recurrent respiratory papillomatosis: A state-of-the-art review. Respir Med. 2017 May;126:116-121. doi: 10.1016/j.rmed.2017.03.030. Epub 2017 Apr 1. PMID: 28427542.
